Coherus BioSciences (NASDAQ:CHRS) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the biotechnology company’s stock.

Separately, Robert W. Baird increased their price target on Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.38.

Coherus BioSciences Price Performance

Shares of NASDAQ:CHRS opened at $1.05 on Tuesday. The company has a market capitalization of $121.68 million, a P/E ratio of -13.13 and a beta of 0.92. Coherus BioSciences has a 1 year low of $0.66 and a 1 year high of $2.64. The business’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.19.

Institutional Investors Weigh In On Coherus BioSciences

A number of large investors have recently modified their holdings of CHRS. Point72 Asset Management L.P. acquired a new stake in shares of Coherus BioSciences in the 4th quarter valued at $7,291,000. Tang Capital Management LLC boosted its holdings in shares of Coherus BioSciences by 55.3% in the 4th quarter. Tang Capital Management LLC now owns 3,650,000 shares of the biotechnology company’s stock valued at $5,037,000 after purchasing an additional 1,300,000 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Coherus BioSciences by 344.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock valued at $967,000 after purchasing an additional 720,672 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Coherus BioSciences by 31.6% in the 4th quarter. Millennium Management LLC now owns 1,049,603 shares of the biotechnology company’s stock valued at $1,448,000 after purchasing an additional 252,092 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Coherus BioSciences in the 4th quarter valued at $345,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.